Shares of Zogenix Inc. (ZGNX) are down over 29%, following mixed results from its global phase III clinical trial of its lead investigational therapy, FINTEPLA in Lennox-Gastaut Syndrome, a severe and treatment-resistant childhood-onset epilepsy.
from RTT - Biotech https://ift.tt/31y1YgB
via IFTTT
No comments:
Post a Comment